Location Preferences for Accessing Long-Acting Injectable Pre-Exposure Prophylaxis (LA-PrEP) Among Men Who Have Sex With Men (MSM) Currently on Daily Oral PrEP.

Jennifer L Glick, Danielle F Nestadt, Travis Sanchez, Kevin Li, Marissa Hannah, M Keith Rawlings, Alex R Rinehart, Supriya Sarkar, Vani Vannappagari
Author Information
  1. Jennifer L Glick: Community Health Science & Policy (CHSP), Louisiana State University, Health Sciences Center, New Orleans, LA, USA. ORCID
  2. Danielle F Nestadt: Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  3. Travis Sanchez: Department Epidemiology, Emory Rollins School of Public Health, Atlanta, GA, USA.
  4. Kevin Li: Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  5. Marissa Hannah: Department Epidemiology, Emory Rollins School of Public Health, Atlanta, GA, USA.
  6. M Keith Rawlings: ViiV Healthcare, Durham, NC, USA.
  7. Alex R Rinehart: ViiV Healthcare, Durham, NC, USA.
  8. Supriya Sarkar: ViiV Healthcare, Durham, NC, USA.
  9. Vani Vannappagari: ViiV Healthcare, Durham, NC, USA.

Abstract

We investigated men who have sex with men's (MSM) location preferences for long-acting injectable pre-exposure prophylaxis (LA-PrEP). MSM (���=���1076) who completed the 2021 American men's Internet Survey, were currently prescribed oral PrEP, and expressed LA-PrEP interest reported location preferences for receiving LA-PrEP: healthcare provider (HCP) setting, pharmacy, or at-home. HCP settings were preferred by 60% of participants; 26% preferred home and 14% preferred pharmacy. In adjusted models, high healthcare stigma was associated with preferring pharmacy and at-home versus HCP, while high friends/family stigma was associated with preferring HCP settings versus pharmacy. Healthcare access history was associated with preference for HCP setting versus home. Being 25 to 29 or 30 to 29 years old versus 40+ was associated with preferring HCP versus home. Private insurance was associated with location preferences. Findings support the need for multiple LA-PrEP service locations to best reach MSM and highlight multiple complex factors that influence such preferences.

Keywords

References

  1. AIDS Behav. 2019 Apr;23(4):847-859 [PMID: 30565095]
  2. AIDS Behav. 2022 Jul;26(7):2425-2434 [PMID: 35076797]
  3. Vital Health Stat 2. 2014 Apr;(166):1-73 [PMID: 24776070]
  4. BMC Public Health. 2022 Dec 16;22(1):2362 [PMID: 36527003]
  5. LGBT Health. 2014 Sep;1(3):225-8 [PMID: 26789716]
  6. PLoS One. 2017 Sep 27;12(9):e0184014 [PMID: 28953905]
  7. Lancet Reg Health Am. 2023 Jan 17;18:100416 [PMID: 36844011]
  8. Patient Prefer Adherence. 2020 Dec 02;14:2365-2375 [PMID: 33293799]
  9. Am J Public Health. 2013 Mar;103(3):e7-e15 [PMID: 23327276]
  10. AIDS Behav. 2019 Jul;23(7):1951-1963 [PMID: 30565092]
  11. AIDS Behav. 2020 Sep;24(9):2520-2531 [PMID: 32052214]
  12. PLoS One. 2017 Dec 27;12(12):e0189794 [PMID: 29281688]
  13. Health Educ Behav. 2013 Feb;40(1):32-41 [PMID: 22505573]
  14. Am J Prev Med. 2021 Nov;61(5 Suppl 1):S60-S72 [PMID: 34686293]
  15. J Am Pharm Assoc (2003). 2020 Jul - Aug;60(4):602-608 [PMID: 32007364]
  16. AIDS Behav. 2023 Nov;27(11):3755-3766 [PMID: 37351685]
  17. J Infect Dis. 2021 Jan 4;223(1):72-82 [PMID: 32882043]
  18. J Assoc Nurses AIDS Care. 2023 Mar-Apr 01;34(2):216-220 [PMID: 36662654]
  19. Prev Med. 2019 Jul;124:98-109 [PMID: 30959070]
  20. JMIR Public Health Surveill. 2019 Feb 04;5(1):e12405 [PMID: 30714945]
  21. AIDS Behav. 2016 Jul;20(7):1400-7 [PMID: 26538056]
  22. Clin Infect Dis. 2019 Jan 18;68(3):501-504 [PMID: 29982304]
  23. Curr HIV/AIDS Rep. 2020 Aug;17(4):281-289 [PMID: 32519185]
  24. AIDS Behav. 2018 Apr;22(4):1158-1164 [PMID: 29119472]
  25. JMIR Public Health Surveill. 2016 Apr 21;2(1):e14 [PMID: 27227149]
  26. AIDS Behav. 2018 Aug;22(8):2413-2425 [PMID: 29948340]
  27. AIDS Care. 2019 May;31(5):545-553 [PMID: 30554519]
  28. LGBT Health. 2018 Aug/Sep;5(6):341-349 [PMID: 30118399]
  29. Adv Ther. 2020 May;37(5):1778-1811 [PMID: 32232664]
  30. Ann Epidemiol. 2018 Dec;28(12):858-864 [PMID: 30406756]
  31. AIDS Behav. 2022 May;26(5):1377-1392 [PMID: 34669062]
  32. Am J Public Health. 2015 Feb;105(2):e75-82 [PMID: 25521875]
  33. AIDS Care. 2019 May;31(5):536-544 [PMID: 30304942]
  34. BMJ Open. 2016 Sep 14;6(9):e011372 [PMID: 27630068]
  35. AIDS Behav. 2019 Nov;23(11):3044-3051 [PMID: 31456200]
  36. Arch Sex Behav. 2018 Oct;47(7):2101-2107 [PMID: 28929260]
  37. Sci Rep. 2023 Mar 29;13(1):5116 [PMID: 36991027]
  38. J Assoc Nurses AIDS Care. 2017 May - Jun;28(3):363-371 [PMID: 28185723]
  39. AIDS Care. 2009 Jun;21(6):742-53 [PMID: 19806490]
  40. Stigma Health. 2024 Aug;9(3):349-361 [PMID: 39185350]
  41. N Engl J Med. 2021 Aug 12;385(7):595-608 [PMID: 34379922]
  42. Digit Health. 2023 Nov 30;9:20552076231217816 [PMID: 38047162]
  43. AIDS Behav. 2021 Mar;25(3):699-708 [PMID: 32910353]
  44. J Acquir Immune Defic Syndr. 2018 Mar 1;77(3):257-263 [PMID: 29140873]
  45. AIDS Behav. 2018 Jul;22(7):2127-2136 [PMID: 28986669]
  46. Curr Opin HIV AIDS. 2020 Jan;15(1):19-26 [PMID: 31644481]
  47. JAMA Netw Open. 2021 Jun 1;4(6):e2110275 [PMID: 34061204]
  48. Curr HIV/AIDS Rep. 2019 Aug;16(4):259-269 [PMID: 31177363]
  49. MMWR Morb Mortal Wkly Rep. 2019 Sep 20;68(37):801-806 [PMID: 31536484]
  50. Am J Health Syst Pharm. 2022 Oct 21;79(21):1898-1905 [PMID: 35894204]
  51. Curr HIV/AIDS Rep. 2021 Dec;18(6):500-507 [PMID: 34708316]
  52. J Int AIDS Soc. 2020 Mar;23(3):e25461 [PMID: 32153119]
  53. BMC Public Health. 2020 Apr 15;20(1):494 [PMID: 32295568]
  54. BMJ Open. 2022 May 11;12(5):e048478 [PMID: 35545381]
  55. PLoS One. 2016 Jun 15;11(6):e0157324 [PMID: 27304883]
  56. Curr Opin HIV AIDS. 2022 Jul 1;17(4):186-191 [PMID: 35762372]
  57. PLoS One. 2018 Jul 19;13(7):e0200296 [PMID: 30024903]
  58. J Int AIDS Soc. 2023 Mar;26(3):e26077 [PMID: 36951057]
  59. AIDS Behav. 2009 Dec;13(6):1160-77 [PMID: 19636699]
  60. Stigma Health. 2018 Nov;3(4):330-337 [PMID: 30662952]
  61. J Int AIDS Soc. 2023 Jul;26 Suppl 2:e26107 [PMID: 37439057]
  62. Open Forum Infect Dis. 2019 Oct 1;6(10): [PMID: 31412131]
  63. Am J Mens Health. 2018 Nov;12(6):1843-1854 [PMID: 30160195]
  64. Am J Prev Med. 2020 Aug;59(2):e79-e87 [PMID: 32376144]
  65. AIDS Patient Care STDS. 2023 Oct;37(10):495-503 [PMID: 37862078]
  66. PLoS One. 2018 Dec 27;13(12):e0209666 [PMID: 30589854]
  67. Clin Infect Dis. 2022 Nov 21;75(Suppl 4):S541-S548 [PMID: 36410385]
  68. J Gen Intern Med. 2019 Apr;34(4):535-543 [PMID: 30719647]
  69. Lancet HIV. 2018 Sep;5(9):e498-e505 [PMID: 29908917]
  70. Curr Opin HIV AIDS. 2016 Jan;11(1):122-8 [PMID: 26633643]

MeSH Term

Humans
Male
Pre-Exposure Prophylaxis
Adult
Homosexuality, Male
HIV Infections
Anti-HIV Agents
Middle Aged
Health Services Accessibility
Patient Preference
Young Adult
Injections
Administration, Oral
Surveys and Questionnaires
Social Stigma
United States

Chemicals

Anti-HIV Agents

Word Cloud

Created with Highcharts 10.0.0HCPMSMassociatedversuspreferencesLA-PrEPPrEPpharmacymenlocationpreferredhomestigmapreferringsexlong-actinginjectablehealthcaresettingat-homesettingshigh29multipleMeninvestigatedmen'spre-exposureprophylaxis���=���1076completed2021AmericanMen'sInternetSurveycurrentlyprescribedoralexpressedinterestreportedreceivingLA-PrEP:provider60%participants26%14%adjustedmodelsfriends/familyHealthcareaccesshistorypreference2530yearsold40+PrivateinsuranceFindingssupportneedservicelocationsbestreachhighlightcomplexfactorsinfluenceLocationPreferencesAccessingLong-ActingInjectablePre-ExposureProphylaxisAmongSexCurrentlyDailyOralHIVrisk

Similar Articles

Cited By

No available data.